Sage Therapeutics: Insider Buying After Recent Debacle [Seeking Alpha]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Seeking Alpha
Summary Today, we take a deeper look at biopharma Sage Therapeutics, whose stock has plunged recently after a major trial disappointment. However, the stock still has 'shots on goal', some remaining analyst support and most importantly; major new insider buying. We take a look at recent events and determine if insiders are now making a wise decision by buying the dip in Sage in the paragraphs below. The inherent vice of capitalism is the unequal sharing of blessings; the inherent vice of socialism is the equal sharing of miseries The small and midcap biotech sectors have enjoyed a nice surge so far during the fourth quarter. A noticeable pick up in activity has buoyed sentiment and stock prices in the sector. One stock that has not participated in this rally is Sage Therapeutics (NASDAQ: SAGE announced The candidate was on par with the placebo which caused a massive sell-off in the stock. We take a look at recent events, new insider buying and whether the market may have thrown out '
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]Yahoo! Finance
- SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
SAGE
Earnings
- 10/29/24 - Miss
SAGE
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form 4
- SAGE's page on the SEC website